EU Joint Clinical Assessments: ATMPs Need ‘More Ambitious' Approach

While the introduction of joint clinical assessments under the new EU HTA Regulation could be “fruitful,” the bloc should take a more “integrated approach” to enabling access to ATMPs, according to a Belgian HTA expert.

EU-wide joint clinical assessments (JCAs), a key part of the Health Technology Assessment (HTA) Regulation, will not solve all access problems faced by EU citizens who are eligible for treatment with an advanced therapy medicinal product (ATMP).

This is according to Jo De Cock, former general administrator for the Belgian HTA body RIZIV-INAMI, who spoke during a...